Search
Citations & References (27)
Gibco™
CTS™ AIM V™ SFM
CTS AIM V SFM is a defined, serum-free medium (SFM) for the proliferation and/or manipulation of T cells, dendritic cells, and other immune cells manufactured in compliance with cGMP.
Have Questions?
Change view
| Catalog Number | Quantity |
|---|---|
| 0870112BK | 10 L |
| 0870112DK | 1 L |
Catalog number 0870112BK
Price (TWD)
46,800.00
Offre exceptionnelle en ligne
Ends: 31-Dec-2025
58,500.00Save 11,700.00 (20%)
Each
Quantity:
10 L
Price (TWD)
46,800.00
Offre exceptionnelle en ligne
Ends: 31-Dec-2025
58,500.00Save 11,700.00 (20%)
Each
Gibco Cell Therapy Systems (CTS) AIM-V SFM is a defined, serum-free medium specifically designed for the proliferation and/or manipulation of T cells, dendritic cells, and other immune cells that is manufactured in compliance with current Good Manufacturing Practice (cGMP) standards.
CTS AIM V SFM contains L-glutamine, 50 μg/mL streptomycin sulfate, and 10 μg/mL gentamicin sulfate.
CTS quality
Gibco CTS products are manufactured at a site that uses methods and controls that conform to cGMP for medical devices, 21 CFR Part 820. Our FDA-registered manufacturing sites are ISO 13485-certified. Gibco CTS products follow USP 'ancillary materials for cell, gene, and tissue-engineered products' within the responsibilities applicable to a supplier.*
Accompanied by documentation to support your regulatory filing
Specific intended-use statements, full documentation traceability, and convenient access to our Drug Master File (DMF) are available.
*Other aspects of USP will be the responsibility of the end-user to assess. Thermo Fisher Scientific cannot fulfill USP in regards to application and therapy-specific aspects (e.g., residual assessment and removal of the Ancillary Material).
For Research Use or Manufacturing of Cell, Gene, or Tissue-Based Products. CAUTION: Not intended for direct administration into humans or animals.
Specifications
Cell TypeMonocytes, Dendritic Cells, T Cells, Hybridomas, PBMCs, Fibroblasts, Macrophages, Myeloma Cells, Lymphocytes
For Use With (Application)Cell and Gene Therapy Research, Development, and Manufacturing
FormatBPC
Manufacturing QualityISO 13485, MDSAP, FDA-registered, 21 CFR 820
Product TypeCell Culture Medium
Quantity10 L
Shelf Life14 months from date of manufacture
Shipping ConditionAmbient
ClassificationAnimal Origin
FormLiquid
Serum LevelSerum-free
SterilitySterile-filtered
Unit SizeEach
Contents & Storage
Store at 2–8°C and protect from light.
Frequently asked questions (FAQs)
Will CTS AIM V SFM (Cat. No. 0870112BK) be discontinued?
Where can I get more information about Aegis 5-14 BPC (BioProcessing Container)?
What type of film is currently used for packaging CTS AIM V SFM (Cat. No. 0870112BK)?
What is the difference between CTS AIM V SFM VALIDATION (Cat. No. A4000311302) and CTS AIM V SFM (Cat. No. 0870112BK)?
What is CTS?
Citations & References (27)
Citations & References
Abstract
Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239.
Journal:J Immunol
PubMed ID:17878372
'HIV-specific CD8+ T cells that secrete multiple cytokines in response to Ag stimulation are associated with the control of virus replication during chronic HIV infection. To determine whether the presence of polyfunctional CD8+ T cell responses distinguishes protected and unprotected monkeys in a live attenuated lentivirus model, SIV Gag peptide-specific
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
Journal:Cancer Immunol Immunother
PubMed ID:19894047
'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause
[Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation]
Journal:Nippon Hinyokika Gakkai Zasshi
PubMed ID:8320888
'We evaluated adoptive immunotherapy using LAK cells combined with systemic administration of interleukin-2 (IL-2) in 11 patients with metastatic renal cell carcinoma. The LAK cells were generated by incubation in serum-free medium (AIM-V) supplemented with IL-2 (1,000 U/ml) for 4 days and were generally administered twice weekly (4 times/cycle). Daily
Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway.
Journal:J Biol Chem
PubMed ID:11812790
'In tyrosinase-positive amelanotic melanoma cells, inactive tyrosinase accumulates in the endoplasmic reticulum. Based on studies described here, we propose that aberrant vacuolar proton ATPase (V-ATPase)-mediated proton transport in melanoma cells disrupts tyrosinase trafficking through the secretory pathway. Amelanotic but not melanotic melanoma cells or normal melanocytes display elevated proton export
Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection.
Journal:J Immunol Methods
PubMed ID:18242633
'The identification of parameters maximizing detection sensitivity in ELISpot assays is important to transfer this technology into the clinical setting for identifying rare Ag-specific CD8(+) T cells. We have therefore considered human IFN-gamma CD8(+) T cell responses against viral epitopes to analyze different variables which could be critical during the